dpp 4 inhibitor and glp 1 agonist Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1 A Comprehensive Review on Dipeptidyl

2019 Apr;37(2):175-181

doi: 10.2337/diabetes.53.9.2397 36 JainMCarlsonGCookWMorrowLPetroneMWhiteNEet al

GLP-1RA Liraglutide Semaglutide Efpeglenatide Glucose lowering effect CV system protection effect Kidney protection effect Nonalcoholic fatty liver disease GIP/GLP1 receptor coagonists: tirzepatide Amylin/GLP1 receptor coagonists: CagriSema (cagrilintide+semaglutide) Glucagon/GLP1 receptor coagonists: survodutide GIP/GLP1/glucagon receptor triple coagonists: retatrutide Obesity is a disease that can be treated with targeted pharmacotherapy in addition to lifestyle modification and behavioral interventions

10.1016/j.cell.2017.09.044 96 WuC.-Y.YangY.-H.LinY.-S.ChangG.-H.TsaiM.-S.HsuC.-M.et al (2021)